Perhaps because it was anticipating investor anxiety about unimpressive sales figures for three drugs partnered with Sanofi, Regeneron Pharmaceuticals Inc. used much of its first quarter earnings call May 3 to talk up its anticipated first immuno-oncology approval later this year with cemiplimab in cutaneous squamous cell carcinoma.
The Tarrytown, N.Y.-based firm outlined its development plans for the PD-1 targeting antibody and offered details on how it expects...








